Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Healthy
Interventions
DRUG

Lacosamide (LCM)

"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"

DRUG

Carbamazepine Immediate Release (CBZ-IR)

"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."

Trial Locations (2)

Unknown

001, Atlanta

002, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY